Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 10
Submit an article Journal homepage
1,481
Views
12
CrossRef citations to date
0
Altmetric
Drug Evaluation

Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma

Estelle BourbonFaculté de Médecine Lyon-SudBernard, Hospices Civils De Lyon, Lyon-Sud, Department Of Hematology, Pierre-Bénite France And Université De Lyon, Université Claude, Oullins, FranceView further author information
&
Gilles SallesFaculté de Médecine Lyon-SudBernard, Hospices Civils De Lyon, Lyon-Sud, Department Of Hematology, Pierre-Bénite France And Université De Lyon, Université Claude, Oullins, FranceCorrespondence[email protected]
View further author information
Pages 1079-1088 | Received 01 Apr 2020, Accepted 21 Jul 2020, Published online: 12 Aug 2020

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Natsumi Kawasaki, Mayu Tomita, Yoriko Yamashita-Kashima, Yasushi Yoshimura & Shigeki Yoshiura. (2023) Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models. Leukemia & Lymphoma 0:0, pages 1-11.
Read now
Aïda Falgàs, Victor Pallarès, Ugutz Unzueta, Yáiza Núñez, Jorge Sierra, Alberto Gallardo, Lorena Alba-Castellón, Maria Antonia Mangues, Patricia Álamo, Antonio Villaverde, Esther Vázquez, Ramon Mangues & Isolda Casanova. (2021) Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine 16, pages 1869-1888.
Read now

Articles from other publishers (10)

Alice Barros Câmara & Igor Augusto Brandão. (2024) The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis. Recent Patents on Anti-Cancer Drug Discovery 19:1, pages 93-120.
Crossref
Brian Effer, Isabela Perez, Daniel Ulloa, Carolyn Mayer, Francisca Muñoz, Diego Bustos, Claudio Rojas, Carlos Manterola, Luis Vergara-Gómez, Camila Dappolonnio, Helga Weber & Pamela Leal. (2023) Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging. Biomedicines 11:7, pages 2086.
Crossref
M. Tommy Gambles, Jiyuan Yang & Jindřich Kopeček. (2023) Multi-targeted immunotherapeutics to treat B cell malignancies. Journal of Controlled Release 358, pages 232-258.
Crossref
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston & Sophia N. Karagiannis. (2023) Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers 15:6, pages 1845.
Crossref
Roberto Ciarcia, Consiglia Longobardi, Gianmarco Ferrara, Serena Montagnaro, Emanuela Andretta, Francesco Pagnini, Salvatore Florio, Lucianna Maruccio, Chiara Lauritano & Sara Damiano. (2022) The Microalga Skeletonema marinoi Induces Apoptosis and DNA Damage in K562 Cell Line by Modulating NADPH Oxidase. Molecules 27:23, pages 8270.
Crossref
Jing Shen & Jinghua Liu. (2022) Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. Frontiers in Oncology 12.
Crossref
Hui Feng, Yi Liu, Mengyao Zhang, Ruimin Liu, Jincheng Wang, Wenjuan Wang, Pengcheng He, Penghui Zhang & Fan Niu. (2022) De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy. Biochemical and Biophysical Research Communications 629, pages 152-158.
Crossref
Yurou Chu, Xiangxiang Zhou & Xin Wang. (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. Journal of Hematology & Oncology 14:1.
Crossref
Assunta Saide, Sara Damiano, Roberto Ciarcia & Chiara Lauritano. (2021) Promising Activities of Marine Natural Products against Hematopoietic Malignancies. Biomedicines 9:6, pages 645.
Crossref
Hongrui Tian, Yakui Huang, Jinlin He, Mingzu Zhang & Peihong Ni. (2021) CD147 Monoclonal Antibody Targeted Reduction-Responsive Camptothecin Polyphosphoester Nanomedicine for Drug Delivery in Hepatocellular Carcinoma Cells. ACS Applied Bio Materials 4:5, pages 4422-4431.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.